Mirabegron

also known as YM178 · myrbetriq · Betanis · Betmiga · BR9006-2 · mirabegron OCAS · mirabegron, which is Myrbetriq (TM) by Astellas Pharma · Mirbetriq · +2 more

Other / unclassified targets ADRB3 via activation

Developed for: overactive bladder · benign prostatic hyperplasia · obesity disorder · prediabetes syndrome · urinary bladder disorder · enuresis · nephrolithiasis · type 2 diabetes mellitus
+33 more
· achalasia · acquired polycythemia vera · colorectal cancer · diffuse large B-cell lymphoma · erectile dysfunction · essential thrombocythemia · head and neck squamous cell carcinoma · hypotensive disorder · interstitial cystitis · intracerebral hemorrhage · low compliance bladder · malignant pancreatic neoplasm · multiple sclerosis · neoplasm · nocturnal enuresis · non-small cell lung carcinoma · ovarian carcinoma · Parkinson disease · postural orthostatic tachycardia syndrome · primary myelofibrosis · small cell lung carcinoma · triple-negative breast carcinoma · ureterolithiasis · urinary tract obstruction · ventricular tachycardia · advanced heart failure · heart disorder · heart failure · metabolic syndrome X · orthostatic hypotension · posterior urethral valve · pulmonary hypertension · ureteral obstruction
Investigated by: Astellas Pharma Inc · Astellas Pharma Europe B.V. · Astellas Pharma Global Development, Inc. · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Far Eastern Memorial Hospital · Astellas Pharma Inc
+61 more
· Buddhist Tzu Chi General Hospital · Indiana University · Astellas Pharma Europe Ltd. · Astellas Pharma US, Inc. · CHU de Quebec-Universite Laval · Cedars-Sinai Medical Center · Kessler Foundation · Mansoura University · Office of Naval Research (ONR) · Philip Kern · Seoul National University Hospital · University of Aarhus · University of Sherbrooke · Zhejiang Provincial People's Hospital · Aaron Cypess · Astellas Pharma Inc · Astellas Pharma Taiwan, Inc. · Astellas Scientific & Medical Affairs, Inc. · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Boryung Pharmaceutical Co., Ltd · Canadian Urological Association · Chang Gung Memorial Hospital · China Medical University Hospital · Christopher Bell · Dong-A ST Co., Ltd. · HealthPartners Institute · Il-Yang Pharm. Co., Ltd. · James J. Peters Veterans Affairs Medical Center · Johns Hopkins University · Laval University · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Loyola University · Mackay Medical College · Mackay Memorial Hospital · National Institute on Aging (NIA) · National Institute on Disability, Independent Living, and Rehabilitation Research · National Institutes of Health (NIH) · National Taiwan University Hospital · Nova Scotia Health Authority · Obstetrics & Gynecology Hospital of Fudan University · Otto Muzik · Peking Union Medical College Hospital · Philadelphia Urosurgical Associates · Samsung Medical Center · Sisters of the Third Order of St. Francis · Southern Illinois University · State University of New York at Buffalo · Swiss Cancer Institute · Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation · Taipei Veterans General Hospital, Taiwan · The University of Texas Health Science Center at San Antonio · Theodore R. Brown, MD MPH · Thomas Jefferson University · Tianjin Medical University General Hospital · Unity Health Toronto · University of Alabama at Birmingham · University of California, San Diego · University of California, San Francisco · University of Manitoba · University of Pittsburgh · Yonsei University

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (2)	US (FDA)	MYRBETRIQ	—	2018-04-27 – 2021-03-25	fda.gov ↗
Approved	EU (EMA)	Betmiga	—	2012-12-20	europa.eu ↗
Approved	US (FDA)	MYRBETRIQ	—	2012-06-28	fda.gov ↗

Trials 123 · started per year

today

US approved 2012

EU approved 2012

200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT06011265	Apr 2023 → Jan 2024	—	Christopher Bell	Completed	No outcome recorded
Phase 0	NCT03612401	Dec 2018 → Mar 2020	spinal cord injury	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 0	NCT03411252	Feb 2018 → Dec 2019	achalasia	Thomas Jefferson University	Terminated	No outcome recorded
Phase 134 trials
Phase 1	NCT05992428	Aug → Nov 2023	—	Dong-A ST Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT05634174	Aug 2023 → Sep 2025 overdue	prediabetes syndrome	University of California, San Diego	Active not recruiting	No outcome recorded
Phase 1	NCT04485585	Jul → Aug 2020	benign prostatic hyperplasia, overactive bladder	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 1	NCT03049462	Mar 2017 → Sep 2026 expected	polycystic ovary syndrome	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Recruiting	No outcome recorded
Phase 1	NCT02526979	Dec 2015 → Sep 2016	overactive bladder	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 1	NCT02211846	Sep 2014 → Sep 2015	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT02169713	May → Aug 2014	—	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 1	NCT02127034	Mar → Jun 2014	—	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 1	NCT02010944	Sep → Nov 2012	—	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 1	NCT01747564	Aug → Oct 2012	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01720212	May → Aug 2012	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01334905	Mar → Jun 2011	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01284309	Nov 2010 → Feb 2011	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01489696	Aug 2010 → Feb 2011	cardiovascular disorder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01199523	May → Nov 2010	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT00965926	Jul → Sep 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01284868	Jul → Nov 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT00939757	May → Jul 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT00940121	Apr → Jul 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01285596	Mar → Nov 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01297192	Mar → Jul 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01579461	Nov 2008 → Apr 2009	—	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 1	NCT01297179	Oct 2008 → Mar 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT00776516	Oct → Dec 2008	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01478568	Oct 2008 → Jan 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01663961	Sep → Dec 2008	—	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 1	NCT00856570	Sep → Dec 2008	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT00750620	Sep 2008 → Sep 2009	impaired renal function disease	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01476800	Jul → Nov 2006	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01478529	Feb → Mar 2006	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01478503	May → Oct 2005	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT01646294	Jan → May 2005	—	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 1	NCT01651312	Jan → Feb 2003	metabolic disease	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 1	NCT01478490	Sep → Nov 2002	—	Astellas Pharma Inc	Completed	No outcome recorded

Phase 1/24 trials
Phase 1/2	NCT05990387	Jul 2023 → Apr 2024	—	Indiana University	Completed	No outcome recorded
Phase 1/2	NCT05240456	Feb → Jul 2022	overactive bladder	Mansoura University	Unknown	No outcome recorded
Phase 1/2	NCT04766021	Nov 2021 → Apr 2023	—	Indiana University	Completed	No outcome recorded
Phase 1/2	NCT02916693	Aug 2017 → Jan 2020	erectile dysfunction, overactive bladder	Johns Hopkins University	Completed	No outcome recorded
Phase 220 trials
Phase 2	NCT05713799	Jul 2026 → Mar 2030 expected	obesity disorder	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Not yet recruiting	No outcome recorded
Phase 2	NCT07566208	May 2026 → May 2028 expected	ventricular tachycardia	Cedars-Sinai Medical Center	Not yet recruiting	No outcome recorded
Phase 2	NCT07585513	May 2026 → May 2028 expected	postural orthostatic tachycardia syndrome	Cedars-Sinai Medical Center	Not yet recruiting	No outcome recorded
Phase 2	NCT06534762	Jul 2024 → Jul 2026 overdue	colorectal cancer, diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, malignant pancreatic neoplasm +3	Zhejiang Provincial People's Hospital	Recruiting	No outcome recorded
Phase 2	NCT06181591	Apr 2024 → Apr 2025	overactive bladder	Seoul National University Hospital	Unknown	No outcome recorded
Phase 2	NCT05369351	Jan 2024 → Aug 2026 overdue	intracerebral hemorrhage	Tianjin Medical University General Hospital	Recruiting	No outcome recorded
Phase 2	NCT04666636	Dec 2020 → Jun 2027 expected	prediabetes syndrome	Philip Kern	Recruiting	No outcome recorded
Phase 2	NCT03187795	Apr 2019 → Sep 2021	spinal cord injury, urinary bladder disorder	Kessler Foundation	Unknown	No outcome recorded
Phase 2	NCT03632772	Aug 2018 → Jul 2019	overactive bladder	Buddhist Tzu Chi General Hospital	Unknown	No outcome recorded
Phase 2	NCT02893553	Dec 2016 → Dec 2021	autonomic dysreflexia, cognitive disorder, hypotensive disorder, spinal cord injury	James J. Peters Veterans Affairs Medical Center	Completed	No outcome recorded
Phase 2	NCT02354807	Oct 2015 → Oct 2017	hibernoma	Otto Muzik	Unknown	No outcome recorded
Phase 2	NCT02462837	May 2015 → Jan 2019	overactive bladder	Southern Illinois University	Terminated	No outcome recorded
Phase 2	NCT02311569	Apr 2015 → Dec 2016	acquired polycythemia vera, essential thrombocythemia, primary myelofibrosis	Swiss Cancer Institute	Completed	No outcome recorded
Phase 2	NCT01950520	Feb 2014 → Dec 2022	—	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 2	NCT01783470	Feb 2013 → Oct 2014	obesity disorder	Aaron Cypess	Completed	No outcome recorded
Phase 2	NCT01340027	Mar 2011 → Jun 2012	overactive bladder	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 2	NCT00527033	Sep 2007 → Apr 2008	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 2	NCT00410514	Dec 2006 → Aug 2008	urinary tract obstruction	Astellas Pharma Inc	Completed	No outcome recorded
Phase 2	NCT01604928	Apr 2004 → Jan 2005	overactive bladder	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 2	NCT00337090	? → Mar 2007	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT06791460	Mar 2025 → Feb 2028 expected	ovarian carcinoma	Obstetrics & Gynecology Hospital of Fudan University	Recruiting	No outcome recorded
Phase 2/3	NCT02044510	Jul 2014 → Jan 2018	urinary bladder disorder	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Terminated	No outcome recorded
Phase 324 trials
Phase 3	NCT07017439	Aug → Dec 2025 overdue	benign prostatic hyperplasia	University of Manitoba	Not yet recruiting	No outcome recorded
Phase 3	NCT07199894	Dec 2024 → Dec 2025 overdue	nocturnal enuresis	Mansoura University	Recruiting	No outcome recorded
Phase 3	NCT06551246	Jun 2024 → Oct 2027 expected	enuresis	University of Aarhus	Recruiting	No outcome recorded
Phase 3	NCT05621616	Feb 2024 → Feb 2026 overdue	overactive bladder	Astellas Pharma Global Development, Inc.	Active not recruiting	No outcome recorded
Phase 3	NCT04641975	Mar 2021 → Jul 2023	overactive bladder	Astellas Pharma Global Development, Inc.	Terminated	No outcome recorded
Phase 3	NCT04286152	Feb 2020 → Feb 2021	nephrolithiasis	Unity Health Toronto	Unknown	No outcome recorded
Phase 3	NCT04023253	Aug 2019 → Dec 2024	overactive bladder	Far Eastern Memorial Hospital	Unknown	No outcome recorded
Phase 3	NCT02787083	Aug 2016 → Jul 2019	interstitial cystitis	Philadelphia Urosurgical Associates	Terminated	No outcome recorded
Phase 3	NCT02751931	Jun 2016 → Nov 2018	overactive bladder	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 3	NCT03044912	Nov 2015 → Feb 2019	overactive bladder	Buddhist Tzu Chi General Hospital	Unknown	No outcome recorded
Phase 3	NCT03059134	Apr 2015 → Apr 2016	overactive bladder	Buddhist Tzu Chi General Hospital	Completed	No outcome recorded
Phase 3	NCT02045862	Mar 2014 → Sep 2016	overactive bladder	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 3	NCT01972841	Nov 2013 → Oct 2015	overactive bladder	Astellas Pharma Europe B.V.	Completed	No outcome recorded
Phase 3	NCT01908829	Jul 2013 → Nov 2014	overactive bladder	Astellas Pharma Europe Ltd.	Completed	No outcome recorded
Phase 3	NCT02468830	Apr 2013 → Jan 2016	overactive bladder	CHU de Quebec-Universite Laval	Completed	No outcome recorded
Phase 3	NCT02476175	Apr 2013 → Apr 2016	overactive bladder	CHU de Quebec-Universite Laval	Completed	No outcome recorded
Phase 3	NCT01638000	Jun 2012 → Apr 2013	overactive bladder	Astellas Pharma Europe Ltd.	Completed	No outcome recorded
Phase 3	NCT01043666	Dec 2009 → Sep 2011	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00966004	Jul 2009 → Feb 2010	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00912964	Apr 2009 → Apr 2010	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00840645	Dec 2008 → Mar 2010	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00689104	Apr 2008 → Mar 2009	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00688688	Apr 2008 → May 2010	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00662909	Mar 2008 → Apr 2009	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded

Phase 430 trials
Phase 4	NCT07310797	Feb 2026 → Dec 2029 expected	ureterolithiasis	Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation	Recruiting	No outcome recorded
Phase 4	NCT06465576	May 2024 → Dec 2027 expected	enuresis	University of Aarhus	Active not recruiting	No outcome recorded
Phase 4	NCT05946902	Sep 2023 → Jul 2024	overactive bladder	Far Eastern Memorial Hospital	Unknown	No outcome recorded
Phase 4	NCT05604222	Mar 2023 → Jun 2026 overdue	overactive bladder	University of Pittsburgh	Active not recruiting	No outcome recorded
Phase 4	NCT05452434	Jul 2022 → Jul 2023	overactive bladder	Peking Union Medical College Hospital	Unknown	No outcome recorded
Phase 4	NCT05051436	Dec 2021 → Aug 2026 overdue	obesity disorder, prediabetes syndrome	Philip Kern	Recruiting	No outcome recorded
Phase 4	NCT05188742	Nov 2021 → Sep 2023	overactive bladder	Taipei Veterans General Hospital, Taiwan	Unknown	No outcome recorded
Phase 4	NCT05968885	Oct 2021 → Jun 2026 overdue	overactive bladder	Mackay Memorial Hospital	Recruiting	No outcome recorded
Phase 4	NCT04907032	Oct 2021 → Apr 2023	overactive bladder	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 4	NCT04909255	Mar 2021 → Aug 2022	Sjogren syndrome, overactive bladder	China Medical University Hospital	Unknown	No outcome recorded
Phase 4	NCT04562090	Jan 2021 → Mar 2022	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT04501640	Sep → Oct 2020	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT03695822	Dec 2018 → Jan 2019	overactive bladder	Far Eastern Memorial Hospital	Withdrawn	No outcome recorded
Phase 4	NCT02981459	Dec 2017 → Jun 2018	urinary bladder disorder	State University of New York at Buffalo	Withdrawn	No outcome recorded
Phase 4	NCT03251300	Aug 2017 → Dec 2024	overactive bladder	Far Eastern Memorial Hospital	Unknown	No outcome recorded
Phase 4	NCT03558919	Jan → Dec 2017	overactive bladder	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Completed	No outcome recorded
Phase 4	NCT02757768	Jun 2016 → Aug 2018	benign prostatic hyperplasia, overactive bladder	Astellas Pharma Global Development, Inc.	Completed	No outcome recorded
Phase 4	NCT02436889	Feb 2016 → Dec 2017	overactive bladder	University of California, San Francisco	Completed	No outcome recorded
Phase 4	NCT02656173	Jan 2016 → Jul 2017	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT02536976	Dec 2015 → Aug 2018	Parkinson disease, cognitive disorder, overactive bladder	HealthPartners Institute	Completed	No outcome recorded
Phase 4	NCT02540707	Sep 2015 → Aug 2020	overactive bladder	National Taiwan University Hospital	Completed	No outcome recorded
Phase 4	NCT02468375	Jun 2015 → Oct 2017	overactive bladder	Samsung Medical Center	Completed	No outcome recorded
Phase 4	NCT02361502	Feb 2015 → Jan 2016	overactive bladder	Seoul National University Hospital	Unknown	No outcome recorded
Phase 4	NCT02495389	Jan 2015 → Jan 2019	overactive bladder	Loyola University	Completed	No outcome recorded
Phase 4	NCT02216214	Oct 2014 → Nov 2017	overactive bladder	Astellas Pharma Global Development, Inc.	Completed	No outcome recorded
Phase 4	NCT02138747	Jul 2014 → Oct 2015	overactive bladder	Astellas Pharma Global Development, Inc.	Completed	No outcome recorded
Phase 4	NCT02086188	May 2014 → Apr 2019	multiple sclerosis	Theodore R. Brown, MD MPH	Completed	No outcome recorded
Phase 4	NCT02095665	Jan 2014 → Mar 2018	nephrolithiasis	Nova Scotia Health Authority	Completed	No outcome recorded
Phase 4	NCT01964183	Jun → Aug 2013	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT01745094	Oct 2012 → Jul 2013	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded

Phase not applicable6 trials
—	NCT07025642	Jul 2025 → May 2026 overdue	overactive bladder	Mackay Medical College	Recruiting	No outcome recorded
—	NCT05779514	Aug 2022 → Dec 2023	neoplasm	Zhejiang Provincial People's Hospital	Unknown	No outcome recorded
—	NCT04823442	Jan 2021 → Apr 2022	type 2 diabetes mellitus	University of Sherbrooke	Completed	No outcome recorded
—	NCT04420533	Jun 2020 → May 2022	overactive bladder, sexual disorder	Chang Gung Memorial Hospital	Completed	No outcome recorded
—	NCT02811289	Aug 2016 → May 2018	type 2 diabetes mellitus	University of Sherbrooke	Completed	No outcome recorded
—	NCT05745584	Jan 2016 → Mar 2023	low compliance bladder	Yonsei University	Unknown	No outcome recorded

Also used as a comparator or background therapy in 42 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT07016451 Background	Apr 2024 → Sep 2025	radiation cystitis	Ramathibodi Hospital	Completed	No outcome recorded
Phase 0	NCT05880862 Comparator	Sep 2023 → Dec 2025	overactive bladder	The University of Texas Medical Branch, Galveston	Completed	No outcome recorded
Phase 0	NCT07447518 Comparator	Sep 2022 → Jan 2023	—	Kafrelsheikh University	Completed	No outcome recorded
Phase 0	NCT02919176 Comparator	Sep 2016 → Feb 2019	metabolic syndrome X, obesity disorder	Philip Kern	Completed	No outcome recorded
Phase 11 trial
Phase 1	NCT06181019 Comparator	Dec 2021 → Mar 2023	overactive bladder	The Affiliated Ganzhou Hospital of Nanchang University	Unknown	No outcome recorded
Phase 28 trials
Phase 2	NCT07261683 Background	Dec 2025 → Nov 2027 expected	ovarian cancer	Obstetrics & Gynecology Hospital of Fudan University	Recruiting	No outcome recorded
Phase 2	NCT06133075 Comparator	Dec 2023 → May 2025	orthostatic hypotension, postural orthostatic tachycardia syndrome	Cedars-Sinai Medical Center	Completed	No outcome recorded
Phase 2	NCT03600766 Comparator	Aug 2018 → Jan 2020	benign prostatic hyperplasia, erectile dysfunction, prostate neoplasm	Mansoura University	Unknown	No outcome recorded
Phase 2	NCT02744430 Comparator	Jul 2017 → Oct 2019	ureteral obstruction	Baylor College of Medicine	Completed	No outcome recorded
Phase 2	NCT03106623 Comparator	Apr → Aug 2017	overactive bladder	Ono Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT02599480 Comparator	Sep 2016 → Feb 2021	heart disorder	Catholic University of Louvain	Completed	No outcome recorded
Phase 2	NCT02775539 Comparator	Jun 2016 → Jan 2017	heart failure, pulmonary hypertension	National Center for Cardiovascular Research Carlos III	Unknown	No outcome recorded
Phase 2	NCT01876433 Comparator	Sep 2013 → Sep 2015	heart failure	Henning Bundgaard	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT03926754 Comparator	Jan 2017 → Jan 2021	advanced heart failure	Henning Bundgaard	Completed	No outcome recorded
Phase 36 trials
Phase 3	NCT06803030 Comparator	Aug → Dec 2025 overdue	—	Bir Hospital	Recruiting	No outcome recorded
Phase 3	NCT07114640 Comparator	Aug 2025 → Dec 2028 expected	overactive bladder	Far Eastern Memorial Hospital	Not yet recruiting	No outcome recorded
Phase 3	NCT07398261 Comparator	Aug 2023 → Sep 2026 expected	nocturnal enuresis	Menoufia University	Active not recruiting	No outcome recorded
Phase 3	NCT05658874 Background	Dec 2022 → Dec 2024	interstitial cystitis, levator syndrome	Jocelyn Fitzgerald	Terminated	No outcome recorded
Phase 3	NCT05490082 Comparator	Mar 2022 → Mar 2023	urinary bladder disorder	Mansoura University	Unknown	No outcome recorded
Phase 3	NCT04325880 Comparator	Dec 2021 → Jun 2022	ureteral disorder	Mansoura University	Unknown	No outcome recorded

Phase 415 trials
Phase 4	NCT07187466 Comparator	Jul 2026 → Mar 2030 expected	Parkinson disease, overactive bladder	VA Office of Research and Development	Not yet recruiting	No outcome recorded
Phase 4	NCT07711808 Comparator	Jul 2026 → Jul 2027 expected	overactive bladder	University of Porto	Not yet recruiting	No outcome recorded
Phase 4	NCT07533565 Comparator	Jul 2024 → Jul 2025	asthma, cirrhosis of liver	Kafrelsheikh University	Completed	No outcome recorded
Phase 4	NCT05806164 Comparator	Jun 2023 → Aug 2026 overdue	overactive bladder	Women and Infants Hospital of Rhode Island	Active not recruiting	No outcome recorded
Phase 4	NCT05362292 Comparator	Oct 2022 → May 2027 expected	overactive bladder	University of California, San Francisco	Recruiting	No outcome recorded
Phase 4	NCT05221021 Comparator	Oct 2022 → Dec 2026 expected	overactive bladder	Walter Reed National Military Medical Center	Recruiting	No outcome recorded
Phase 4	NCT06124066 Comparator	Jul → Sep 2022	nephrolithiasis, stricture or kinking of ureter, ureterolithiasis	Hasanuddin University	Completed	No outcome recorded
Phase 4	NCT06197295 Comparator	Jun 2022 → Jun 2026 overdue	overactive bladder	Mackay Memorial Hospital	Recruiting	No outcome recorded
Phase 4	NCT06479720 Comparator	Jun 2022 → Jun 2026 overdue	overactive bladder	Mackay Memorial Hospital	Recruiting	No outcome recorded
Phase 4	NCT02279615 Comparator	Dec 2021 → Dec 2022	benign prostatic hyperplasia, overactive bladder	St. Joseph's Healthcare Hamilton	Unknown	No outcome recorded
Phase 4	NCT03817931 Comparator	Aug 2019 → Feb 2022	dementia, overactive bladder	Baylor Research Institute	Completed	No outcome recorded
Phase 4	NCT03412513 Comparator	Jul 2017 → Jul 2018	Parkinson disease, overactive bladder	Seoul National University Hospital	Unknown	No outcome recorded
Phase 4	NCT03012113 Comparator	Jun 2016 → Jun 2017	obesity disorder	Ingrid Jazet	Unknown	No outcome recorded
Phase 4	NCT02294396 Background	Oct 2014 → Sep 2016	overactive bladder	Astellas Pharma Inc	Completed	No outcome recorded
Phase 4	NCT02092181 Comparator	Mar 2014 → Jul 2018	Parkinson disease	Daniel Burdick, MD	Completed	No outcome recorded

Phase not applicable7 trials
—	NCT07259148 Comparator	Nov 2025 → Jan 2026 overdue	overactive bladder	Emilio José Dávila Álvarez	Active not recruiting	No outcome recorded
—	NCT07668232 Comparator	Jan → Dec 2025	posterior urethral valve	South Valley University	Completed	No outcome recorded
—	NCT07307261 Comparator	Oct 2024 → Oct 2025	—	Avraiem Talaat	Completed	No outcome recorded
—	NCT05617664 Comparator	Nov 2022 → Sep 2023	nocturnal enuresis	Benha University	Unknown	No outcome recorded
—	NCT06184334 Comparator	Sep → Dec 2022	overactive bladder	Elsayed Abdelhalim Elsayed	Completed	No outcome recorded
—	NCT06123364 Comparator	Oct 2019 → Apr 2023	overactive bladder	Serdinsek Tamara	Completed	No outcome recorded
—	NCT03087578 Comparator	Jul 2017 → Jul 2018	overactive bladder	University Hospitals Cleveland Medical Center	Withdrawn	No outcome recorded

Evidence & citations 15 cited values

Every value below carries the sentence it was read from. 168 sources stand behind the page.

Field	Value	Cited text
Known as	Mirabegron	“Here we determined the ability of 200 mg oral mirabegron (Myrbetriq, Astellas Pharma, Inc.), a β3-AR agonist currently approved to treat overactive bladder, to stimulate BAT as...” PMID 25565203 ↗ Jan 2015 148 “Mirabegron (Myrbetriq®, extended-release tablet, Astellas Pharma), is a medication approved by the Food and Drug Administration for the treatment of overactive bladder.” NCT06011265 ↗ “About 100 patients will receive Mirabegron (50mg) once daily for 3 weeks for the treatment of lower urinary tract symptoms related to double j stent in adults” NCT07307261 ↗ “The beta 3 agonist ,Mirabegron, has been shown to be effective for the treatment of OAB in adults through relaxation of bladder wall, with few side effects.” NCT05240456 ↗ “Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers” NCT01720212 ↗ “Overactive Bladder Medication( Trospium/Oxybutynin/Detrol vs. Mirabegron)” NCT05658874 ↗ “Mirabegron 25 mg tablet orally once daily for 30 days” NCT03817931 ↗ “* Mirabegron Pain Control Medications” NCT07016451 ↗ “Solifenacin 5mg and Mirabegron 25mg” NCT06197295 ↗ NCT00689104 ↗ NCT05968885 ↗ NCT03251300 ↗ NCT02169713 ↗ NCT02495389 ↗ NCT07668232 ↗ NCT03059134 ↗ NCT02599480 ↗ NCT07533565 ↗ NCT07017439 ↗ NCT02751931 ↗ NCT01950520 ↗ NCT05188742 ↗ NCT04562090 ↗ NCT07447518 ↗ NCT01972841 ↗ NCT02216214 ↗ NCT03558919 ↗ NCT06123364 ↗ NCT02462837 ↗ NCT06124066 ↗ NCT02279615 ↗ NCT06479720 ↗ NCT03049462 ↗ NCT04823442 ↗ NCT07398261 ↗ NCT01478490 ↗ NCT03926754 ↗ NCT07261683 ↗ NCT07259148 ↗ NCT02757768 ↗ NCT05806164 ↗ NCT01964183 ↗ NCT02775539 ↗ NCT05992428 ↗ NCT01478503 ↗ NCT00662909 ↗ NCT01284309 ↗ NCT05990387 ↗ NCT05634174 ↗ NCT04766021 ↗ NCT02138747 ↗ NCT02436889 ↗ NCT02526979 ↗ NCT01478529 ↗ NCT07114640 ↗ NCT05369351 ↗ NCT05452434 ↗ NCT02095665 ↗ NCT06181019 ↗ NCT06181591 ↗ NCT02919176 ↗ NCT06133075 ↗ NCT02010944 ↗ NCT05490082 ↗ NCT01876433 ↗ NCT03632772 ↗ NCT05621616 ↗ NCT03106623 ↗ NCT06184334 ↗ NCT01579461 ↗ NCT04325880 ↗ NCT01284868 ↗ NCT02476175 ↗ NCT04909255 ↗ NCT02211846 ↗ NCT04501640 ↗ NCT02656173 ↗ NCT03044912 ↗ NCT06551246 ↗ NCT02811289 ↗ NCT07566208 ↗ NCT01478568 ↗ NCT04666636 ↗ NCT00939757 ↗ NCT01285596 ↗ NCT02893553 ↗ NCT01638000 ↗ NCT06534762 ↗ NCT02044510 ↗ NCT05221021 ↗ NCT03600766 ↗ NCT04286152 ↗ NCT02468375 ↗ NCT04641975 ↗ NCT03087578 ↗ NCT02536976 ↗ NCT00940121 ↗ NCT02981459 ↗ NCT05051436 ↗ NCT01340027 ↗ NCT07199894 ↗ NCT07310797 ↗ NCT04023253 ↗ NCT02540707 ↗ NCT02045862 ↗ NCT05779514 ↗ NCT01908829 ↗ NCT01297179 ↗ NCT03695822 ↗ NCT02294396 ↗ NCT02916693 ↗ NCT01297192 ↗ NCT05362292 ↗ NCT03612401 ↗ NCT05604222 ↗ NCT04907032 ↗ NCT03412513 ↗ NCT05617664 ↗ NCT07187466 ↗ NCT03411252 ↗ NCT02092181 ↗ NCT02787083 ↗ NCT02361502 ↗ NCT06803030 ↗ NCT02127034 ↗ NCT00688688 ↗ NCT00776516 ↗ NCT01489696 ↗ NCT06465576 ↗ NCT07711808 ↗ NCT00410514 ↗ NCT02744430 ↗ NCT02468830 ↗ NCT01199523 ↗ NCT04420533 ↗ NCT03012113 ↗ NCT02354807 ↗ NCT01745094 ↗ NCT05946902 ↗ NCT02086188 ↗ NCT00912964 ↗ NCT03187795 ↗ NCT05713799 ↗ NCT07585513 ↗ NCT02311569 ↗ NCT06791460 ↗ NCT07025642 ↗ NCT05880862 ↗ NCT05745584 ↗
Known as	Betanis	ChEMBL registry synonym — accepted as the source's own label CHEMBL2095212 ↗
Known as	Betmiga	ChEMBL registry synonym — accepted as the source's own label CHEMBL2095212 ↗
Known as	BR9006-2	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04485585 ↗
Known as	mirabegron OCAS	“Drug: mirabegron OCAS” NCT01478529 ↗
Known as	mirabegron, which is Myrbetriq (TM) by Astellas Pharma	“mirabegron, which is Myrbetriq (TM) by Astellas Pharma” NCT01783470 ↗
Known as	Mirbetriq	“Mirbetriq (Mirabegron) (50mg) will be administered orally at time 0 to activate brown adipose tissue.” NCT02811289 ↗
Known as	Mybetriq	“Mirabegron, currently sold under the brand name Mybetriq by Astellas Pharma, is a selective beta-3-adrenergic receptor agonist approved for treatment of urgency urinary...” NCT05362292 ↗
Known as	myrbetriq	“Beta-3 agonists (Mirabegron/Myrbetriq)” NCT07017439 ↗ 1 “Mirabegron 50 MG [Myrbetriq]” NCT03087578 ↗
Known as	Myrbetriq granules	ChEMBL registry synonym — accepted as the source's own label CHEMBL2095212 ↗
Known as	YM178	“A Phase 1, Open-Label, Drug Interaction Study to Evaluate the Effect of Repeat Doses of Rifampin on the Single-Dose Pharmacokinetics of Mirabegron (YM178)” NCT00776516 ↗ 18 “The study aims to compare blood and urine concentrations of mirabegron (YM178) in healthy poor or extensive metabolizers for CYP2D6” NCT01478490 ↗ “mirabegron (YM178)” NCT01297192 ↗ NCT00750620 ↗ NCT01651312 ↗ NCT01646294 ↗ NCT00337090 ↗ NCT01043666 ↗ NCT00840645 ↗ NCT00856570 ↗ NCT01334905 ↗ NCT01604928 ↗ NCT00527033 ↗ NCT01663961 ↗ NCT01720212 ↗ NCT01747564 ↗ NCT01476800 ↗ NCT00965926 ↗ NCT00966004 ↗
Action	Activate	“β3 -adrenoceptor agonist” PMID 26663687 ↗ Mar 2014
Modality	Other / unclassified	“β3 -adrenoceptor agonist” PMID 26663687 ↗ Mar 2014
Route	Oral	“Oral” NCT00527033 ↗
Target	ADRB3	“ADRB3 agonist” NCT05634174 ↗